Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases

被引：47

作者：

Guan, Shi-Yang ^{[1
,2
]}

Leng, Rui-Xue ^{[1
,2
]}

Khan, Muhammad Imran ^{[1
,2
]}

Qureshi, Humera ^{[1
,2
]}

Li, Xiang-Pei ^{[3
]}

Ye, Dong-Qing ^{[1
,2
]}

Pan, Hai-Feng ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China

[2] Anhui Med Univ, Anhui Prov Lab Populat Hlth & Major Dis Screening, 81 Meishan Rd, Hefei, Anhui, Peoples R China

[3] Anhui Prov Hosp, Dept Rheumatol & Immunol, 17 Lujiang Rd, Hefei, Anhui, Peoples R China

来源：

INFLAMMATION | 2017年 / 40卷 / 01期

基金：

中国国家自然科学基金;

关键词：

interleukin-35; Th17; cells; Treg cells; therapeutic agent; autoimmune diseases; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MESENCHYMAL STEM-CELLS; B-CELLS; TH17/TREG IMBALANCE; INDUCED ARTHRITIS; IMMUNE-RESPONSES; MURINE MODEL; IL-35; CYTOKINE;

D O I：

10.1007/s10753-016-0453-9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.

引用

页码：303 / 310

页数：8

共 50 条

[21] Interleukin-35 takes the 'B' line
Mauri, Claudia
Nistala, Kiran
NATURE MEDICINE, 2014, 20 (06) : 580 - 581
[22] Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases
Ye, Cheng
Yano, Hiroshi
Workman, Creg J.
Vignali, Dario A. A.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2021, 41 (11): : 391 - 406
[23] Interleukin-35 in Idiopathic Inflammatory Myopathies
Mann, Herman F.
Hulejova, Hana
Zamecnik, Josef
Hacek, Jaromir
Filkova, Maria
Krystufkova, Olga
Vencovsky, J.
Senolt, Ladislav
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[24] Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells
Luo, Zhengkang
Lundin, Sara
Mejia-Cordova, Mariela
Hassani, Imane
Blixt, Martin
Hjelmqvist, Daisy
Lau, Joey
Espes, Daniel
Carlsson, Per-Ola
Sandler, Stellan
Singh, Kailash
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
[25] Immunomodulatory cytokine interleukin-35 and immune thrombocytopaenia
Zhu, Jing-Jing
Shan, Ning-Ning
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (12)
[26] The Mechanism of Interleukin-35 in Chronic Hepatitis B
Tang, Ying
Ma, Tianyi
Jia, Shengnan
Zhang, Qian
Liu, Siqi
Qi, Ling
Yang, Lanlan
SEMINARS IN LIVER DISEASE, 2021, 41 (04) : 516 - 524
[27] The Therapeutic Potential of Epigenetics in Autoimmune Diseases
De Santis, Maria
Selmi, Carlo
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2012, 42 (01) : 92 - 101
[28] The Therapeutic Potential of Epigenetics in Autoimmune Diseases
Maria De Santis
Carlo Selmi
Clinical Reviews in Allergy & Immunology, 2012, 42 : 92 - 101
[29] Regulatory T Cells and Their Derived Cytokine, Interleukin-35, Reduce Pain in Experimental Autoimmune Encephalomyelitis
Duffy, Samuel S.
Keating, Brooke A.
Perera, Chamini J.
Lees, Justin G.
Tonkin, Ryan S.
Makker, Preet G. S.
Carrive, Pascal
Butovsky, Oleg
Moalem-Taylor, Gila
JOURNAL OF NEUROSCIENCE, 2019, 39 (12): : 2326 - 2346
[30] Interleukin-35 as an Emerging Player in Tumor Microenvironment
Xue, Wenhua
Yan, Dan
Kan, Quancheng
JOURNAL OF CANCER, 2019, 10 (09): : 2074 - 2082

← 1 2 3 4 5 →